Related Experiment Video
Updated: Apr 20, 2026

Author Spotlight: 3D Scanning and Augmented Reality for Enhanced Cancer Surgery Communication
Published on: December 15, 2023
Primary care physician supply, insurance type, and late-stage cancer diagnosis
Jesse J Plascak1, James L Fisher2, Electra D Paskett3
1Department of Health Services, School of Public Health, The University of Washington, Seattle, Washington.
Background:
Understanding the joint effects of insurance type and primary care physician density on stage at diagnosis is essential to elucidating the healthcare access and late-stage cancer relationship.
Purpose:
To determine if the relationship between primary care physician density and odds of late-stage cancer are modified by insurance type at diagnosis.
Methods:
Case patients were Ohio adults diagnosed between 1996 and 2008 with cancer of one of the following sites: female breast, cervix, colon/rectum, lung/bronchus, melanoma of the skin, oral cavity and pharynx, or prostate (N=376,425). County-level physician density was obtained from the Ohio Department of Health. Multilevel logistic regression models estimated odds ratios of late-stage cancer diagnosis associated with increases in primary care physician density by insurance type. Analyses were conducted in 2014.
Results:
Decreases in late-stage diagnosis of cancers of the breast, prostate, melanoma of the skin, oral cavity and pharynx, or lung/bronchus associated with increases in primary care physician density were strongest among those with private insurance, whereas those with Medicare (prostate, oral cavity and pharynx, lung/bronchus), Medicaid (lung/bronchus), uninsured (prostate), and other/unknown (prostate, oral cavity and pharynx, lung/bronchus) did not benefit as greatly, or experienced significant increases in late-stage cancer diagnosis (other/unknown [female breast], Medicaid [melanoma of the skin], and uninsured [colon/rectum]).
Conclusions:
As primary care physician density increases, those with private insurance consistently benefit the most in terms of late-stage cancer diagnosis, whereas those with several other insurance types experience flatter decreases or significantly higher odds of late-stage cancer diagnosis.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Survival Analysis
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
Secondary Healthcare System
Treatment Resistant Cancers
Treatment Resistent Cancers

